{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:12:25Z","timestamp":1790035945054,"version":"4.0.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"API-CAT"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The API-CAT trial demonstrated that reduced-dose apixaban (2.5 mg twice daily) was noninferior to full-dose apixaban (5 mg twice daily) for the prevention of recurrent venous thromboembolism in patients with cancer, while resulting in fewer clinically relevant bleeding events. Although these findings are expected to influence clinical practice, real-world data on physicians\u2019 anticoagulation decisions in this setting remain limited. To describe investigators\u2019 anticoagulant treatment decisions for patients enrolled in the API-CAT trial after discontinuation of blinded study treatment and prior to trial unblinding and dissemination of results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This descriptive analysis included patients from the prospective, multicentre, randomized, double-blind API-CAT trial who received at least one dose of study medication. Investigators prospectively documented anticoagulation management following either premature or planned discontinuation of blinded apixaban. Decisions were categorized as treatment discontinuation, continuation at a reduced dose, or continuation at a full dose. Descriptive analyses examined treatment choices according to patient characteristics, cancer features, and contextual factors. Of 1766 randomized patients, 1458 (82.6%) were included in the analysis. After discontinuation of study treatment, anticoagulation was stopped in 198 patients (13.6%) and continued in 1260 (86.4%). Among those continuing therapy, 790 patients (62.7%) received full-dose anticoagulation, 465 (36.9%) received a reduced dose, 5 unknown. Direct oral anticoagulants (DOACs) were prescribed in 89.6% of cases, and low-molecular-weight heparin in 9.9%. Treatment decisions were generally consistent across patient and cancer characteristics but varied according to timing of treatment discontinuation, physician specialty, and country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Prior to unblinding of the API-CAT trial, treatment decisions appeared poorly driven by clinical characteristics, reflecting a \u2018therapeutic grey zone\u2019 where anticoagulation was continued in most patients but with highly variable dosing. This exploratory snapshot provides a baseline to monitor the anticipated shift towards wider adoption of reduced-dose apixaban for extended anticoagulation following publication of the API-CAT results. The substantial proportion of treatment discontinuation highlights the need for further studies to identify patients who may safely stop therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>API-CAT ClinicalTrials.gov number, NCT03692065<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Coordination<\/jats:title>\n                    <jats:p>Assistance Publique H\u00f4pitaux de Paris, France<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvag046","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:45:55Z","timestamp":1782387955000},"page":"447-457","source":"Crossref","is-referenced-by-count":1,"title":["API-CAT investigators\u2019 decisions on anticoagulation following extended treatment for cancer-associated thrombosis"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-7880","authenticated-orcid":false,"given":"Isabelle","family":"Mah\u00e9","sequence":"first","affiliation":[{"name":"Paris Cit\u00e9 University, Paris 75006 ,","place":["France"]},{"name":"Department of Internal Medicine , Louis Mourier Hospital, Assistance-Publique - H\u00f4pitaux de Paris, 178 rue des renouillers, Colombes 92700 ,","place":["France"]},{"name":"Inserm UMR-S970, Paris Cardiovascular Research Center, Team \u00ab Endotheliopathy and Hemostasis Disorders \u00bb , Paris 75015 ,","place":["France"]},{"name":"F-CRIN INNOVTE Network , Saint-Etienne 42055 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7233-681X","authenticated-orcid":false,"given":"Florent","family":"Happe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Louis Mourier Hospital, Assistance-Publique - H\u00f4pitaux de Paris, 178 rue des renouillers, Colombes 92700 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Monreal","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Institut de Recerca Germans Trias I Pujol, Hospital Universitari Germans Trias I Pujol , Badalona 08916 ,","place":["Spain"]},{"name":"Department of Medicine, Universitat Autonoma de Barcelona , Barcelona 08193, Spain"},{"name":"Universidad Catolica San Antonio de Murcia , Murcia 30107 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helia","family":"Robert-Ebadi","sequence":"additional","affiliation":[{"name":"Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals , CH 1211 Geneva 14 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Debourdeau","sequence":"additional","affiliation":[{"name":"Arles Hospital, Oncology Unit , Arles 13200 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Roch","family":"Fabreguettes","sequence":"additional","affiliation":[{"name":"Assistance Publique - H\u00f4pitaux de Paris, AGEPS , Paris 75005 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Accassat","sequence":"additional","affiliation":[{"name":"F-CRIN INNOVTE Network , Saint-Etienne 42055 ,","place":["France"]},{"name":"Service de M\u00e9decine Vasculaire et Therapeutique, CHU de Saint-Etienne , Saint-Etienne 42055 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Mismetti","sequence":"additional","affiliation":[{"name":"F-CRIN INNOVTE Network , Saint-Etienne 42055 ,","place":["France"]},{"name":"Service de M\u00e9decine Vasculaire et Therapeutique, CHU de Saint-Etienne , Saint-Etienne 42055 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1559-8055","authenticated-orcid":false,"given":"Philippe","family":"Girard","sequence":"additional","affiliation":[{"name":"F-CRIN INNOVTE Network , Saint-Etienne 42055 ,","place":["France"]},{"name":"D\u00e9partement de Pneumologie, Institut Mutualiste Montsouris , Paris 75014, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-8668","authenticated-orcid":false,"given":"Silvy","family":"Laporte","sequence":"additional","affiliation":[{"name":"F-CRIN INNOVTE Network , Saint-Etienne 42055 ,","place":["France"]},{"name":"Universit\u00e9 Jean Monnet, Mines Saint-\u00c9tienne, INSERM Unit\u00e9 1059, Sant\u00e9 Ing\u00e9nierie Biologie Saint-\u00c9tienne (SAINBIOSE) , Saint-\u00c9tienne 42023 ,","place":["France"]},{"name":"Service de Pharmacologie Clinique, CHU de Saint-Etienne , Saint-Etienne 42055 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Chapelle","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Jean Monnet, Mines Saint-\u00c9tienne, INSERM Unit\u00e9 1059, Sant\u00e9 Ing\u00e9nierie Biologie Saint-\u00c9tienne (SAINBIOSE) , Saint-\u00c9tienne 42023 ,","place":["France"]},{"name":"Service de Pharmacologie Clinique, CHU de Saint-Etienne , Saint-Etienne 42055 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,26]]},"reference":[{"key":"2026092119571175300_pvag046-B1","author":"NCCN"},{"key":"2026092119571175300_pvag046-B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.acvd.2023.11.010","article-title":"Anticoagulant treatment of cancer-associated thromboembolism","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"2026092119571175300_pvag046-B3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.acvd.2025.07.007","article-title":"The management of cancer-associated thromboembolism: proposals from the French multidisciplinary INNOVTE CAT working group","volume":"118","author":"Mah\u00e9","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"2026092119571175300_pvag046-B4","doi-asserted-by":"publisher","DOI":"10.1055\/a-2645-4927","article-title":"Implications of the API-CAT trial for extended secondary prophylaxis of cancer-associated venous thromboembolism: guidance from an expert panel","author":"Langer","year":"2025","journal-title":"Hamostaseologie"},{"key":"2026092119571175300_pvag046-B5","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1016\/j.jtha.2024.03.011","article-title":"Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial","volume":"22","author":"McBane","year":"2024","journal-title":"J Thromb Haemost"},{"key":"2026092119571175300_pvag046-B6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jth.15599","article-title":"Extended anticoagulation treatment for cancer-associated thrombosis-rates of recurrence and bleeding beyond 6 months: a systematic review","volume":"20","author":"Moik","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026092119571175300_pvag046-B7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/jth.15666","article-title":"Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients\u201430 months follow-up","volume":"20","author":"Larsen","year":"2022","journal-title":"J Thromb Haemost"},{"key":"2026092119571175300_pvag046-B8","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"Mah\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092119571175300_pvag046-B9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.26502\/jcsct.5079122","article-title":"Reasons influencing long-term anticoagulant treatment beyond 6 months for cancer-associated thrombosis in USCAT, a 432-patient retrospective non-interventional study","volume":"5","author":"Plaisance","year":"2021","journal-title":"J Cancer Sci Clin Ther"},{"key":"2026092119571175300_pvag046-B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thromb Res"},{"key":"2026092119571175300_pvag046-B11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092119571175300_pvag046-B12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.acvd.2023.11.006","article-title":"Recurrent venous thromboembolism in anticoagulated cancer patients: diagnosis and treatment","volume":"117","author":"Bertoletti","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"2026092119571175300_pvag046-B13","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1001\/jamaneurol.2018.2598","article-title":"Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies","volume":"75","author":"Mariampillai","year":"2018","journal-title":"JAMA Neurol"},{"key":"2026092119571175300_pvag046-B14","doi-asserted-by":"crossref","DOI":"10.1201\/b21874","volume-title":"Exploratory Multivariate Analysis by Example Using R","author":"Husson","year":"2017"},{"key":"2026092119571175300_pvag046-B15","doi-asserted-by":"crossref","DOI":"10.1201\/9781315369983","volume-title":"Correspondence Analysis in Practice","author":"Greenacre","year":"2017"},{"key":"2026092119571175300_pvag046-B16","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2023.7843","article-title":"Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial","volume":"329","author":"Schrag","year":"2023","journal-title":"JAMA"},{"key":"2026092119571175300_pvag046-B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"2026092119571175300_pvag046-B18","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1159\/000545976","article-title":"CONKO-011\/AIO-SUP-0115\/ass.: rivaroxaban compared to low molecular weight heparin in cancer patients with acute venous thromboembolism","volume":"48","author":"Sinn","year":"2025","journal-title":"Oncol Res Treat"},{"key":"2026092119571175300_pvag046-B19","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0040-1718728","article-title":"Effectiveness and safety of apixaban, low-molecular-weight heparin, and warfarin among venous thromboembolism patients with active cancer: a U.S. Claims data analysis","volume":"121","author":"Cohen","year":"2021","journal-title":"Thromb Haemost"},{"key":"2026092119571175300_pvag046-B20","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.3390\/cancers14174143","article-title":"Management of cancer-associated thrombosis in France: a national survey among vascular disease and supportive care specialists","volume":"14","author":"Mah\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026092119571175300_pvag046-B21","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12604","article-title":"Cancer-associated ThrOmboSIs\u2014patient-reported OutcoMes with RivarOxaban (COSIMO)\u2014baseline characteristics and clinical outcomes","volume":"5","author":"Maraveyas","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2026092119571175300_pvag046-B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2021.06.021","article-title":"Patient-reported outcomes associated with changing to rivaroxaban for the treatment of cancer-associated venous thromboembolism\u2014the COSIMO study","volume":"206","author":"Cohen","year":"2021","journal-title":"Thromb Res"},{"key":"2026092119571175300_pvag046-B23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.acvd.2023.11.002","article-title":"Management of cancer-associated thromboembolism: introduction","volume":"117","author":"Mah\u00e9","year":"2024","journal-title":"Arch Cardiovasc Dis"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvag046\/68630089\/pvag046.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/6\/447\/68630089\/pvag046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/12\/6\/447\/68630089\/pvag046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:57:18Z","timestamp":1790035038000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/12\/6\/447\/8719281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,26]]},"published-print":{"date-parts":[[2026,9,22]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvag046","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,6,26]]}}}